BriaCell Therapeutics Faces Delisting Notice
Ticker: BCTXZ · Form: 8-K · Filed: Aug 23, 2024 · CIK: 1610820
Sentiment: bearish
Topics: delisting, listing-rules, regulatory
Related Tickers: BCT
TL;DR
BriaCell's stock might get delisted, big trouble.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on August 22, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was formerly known as Ansell Capital Corp. and was incorporated in British Columbia.
Why It Matters
This filing indicates potential issues with BriaCell Therapeutics' continued listing on an exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on major exchanges, posing a significant risk to its operations and investors.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- August 22, 2024 (date) — Date of earliest event reported
- British Columbia (jurisdiction) — State of incorporation
FAQ
What is the specific reason for BriaCell Therapeutics Corp.'s notice of delisting or failure to satisfy a continued listing rule?
The provided text of the 8-K filing does not specify the exact reason for the delisting notice, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 22, 2024.
What was BriaCell Therapeutics Corp.'s former company name?
BriaCell Therapeutics Corp.'s former company name was Ansell Capital Corp.
In which jurisdiction was BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. was incorporated in British Columbia.
What is the filing date of this 8-K report?
This 8-K report was filed as of August 23, 2024.
Filing Stats: 877 words · 4 min read · ~3 pages · Grade level 12.9 · Accepted 2024-08-23 17:00:30
Key Financial Figures
- $1.00 — mmon shares have been below the minimum $1.00 per share required for continued listin
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-24-033753.txt ( ) — 252KB
- bct-20240822.xsd (EX-101.SCH) — 4KB
- bct-20240822_def.xml (EX-101.DEF) — 26KB
- bct-20240822_lab.xml (EX-101.LAB) — 36KB
- bct-20240822_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams Date: August 23, 2024 William V. Williams President and Chief Executive Officer